VJHemOnc is committed to improving our service to you

ESH 2017 | Translational research in Berlin to improve AML treatment outcomes

VJHemOnc is committed to improving our service to you

Lars Bullinger

New research methods enable a greater understanding of a disease and allow for more personalized medicine to be produced. In this interview, Lars Bullinger, MD, from Charité University of Medicine, Berlin, Germany, speaking from the International Conference of Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), discusses ongoing translational research in Berlin to characterize acute myeloid leukemia (AML) in all age ranges, with a multitude of aims, including identifying biomarkers and treatment responses, in addition to improving the registries storing this data. Dr Bullinger also describes how he foresees cellular immunotherapies being utilized to treat persistent AML.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter